16 results about "Bortezomib" patented technology

This invention provides the application of the IFI16 gene as a target in the preparation of bortezomib-resistant drugs for the treatment of multiple myeloma, involving drug targets, related diagnostic reagents, and treatment strategies for the diagnosis and treatment of multiple myeloma (MM). This invention reveals for the first time the core driving role of IFI16 in bortezomib resistance in MM and its novel mechanism of action through the Wnt / β-catenin pathway; more importantly, it provides novel biomarkers, drug targets, and highly feasible combination therapy regimens for accurate prognostic assessment of MM and overcoming the clinically challenging problem of bortezomib resistance, possessing significant theoretical implications and broad clinical application prospects.

This invention provides the application of indexsulfanilamide in the preparation of drugs for the prevention and / or treatment of multiple myeloma, belonging to the field of oncology drug technology. Indexsulfanilamide exhibits significant anti-multiple myeloma effects in various multiple myeloma cell lines, primary cells, and multiple myeloma mouse models, and inhibits tumor growth in multiple myeloma mice while demonstrating good safety. Furthermore, the combination of indexsulfanilamide and bortezomib produces a synergistic effect, suggesting that indexsulfanilamide has a promising therapeutic prospect for multiple myeloma.

The invention relates to the technical field of medicines, in particular to a covalent organic framework material loaded with a boron drug compound as well as a preparation method and application of the covalent organic framework material. The covalent organic framework material loaded with the boron drug compound comprises bortezomib and a loading body, and the loading body is prepared from a covalent organic framework material modified by folic acid. The pore size regulation of the triazinyl COF is matched with the molecular size of the boron drug, and the topological structure design (AA stacking mode) of the COF is combined with the dynamic simulation of drug molecules, so that the ultrahigh drug loading capacity (42.7%) and the high retention rate gt of the drug within 72 hours are realized; moreover, folic acid molecules are connected through thioether bonds, so that gt is realized while the COF crystallinity is kept; and the FA surface coverage rate is 85%. The three-in-one design of'structure adaptive drug loading, chemical stable targeting and accurate environment release 'is realized for the first time, an efficient drug delivery platform is provided for advanced therapies such as boron neutron capture therapy (BNCT) and the like, and cross development of anti-cancer drugs from'extensive chemotherapy' to'molecular-level accurate regulation and control 'is promoted.

The invention discloses a bortezomib and illicit loaded targeted copper / calcium bimetal-based nanocage and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out in-situ etching on amorphous calcium carbonate nanospheres by using a copper chloride aqueous solution to form the copper / calcium bimetal-based nanocage; the preparation method comprises the following steps: loading bortezomib and illicit in a nanocage under the coordination action to form a bortezomib and illicit loaded copper / calcium bimetal-based nanocage; and then carrying out surface modification by using hydrazide hyaluronic acid to form the bortezomib and illicit loaded targeted copper / calcium double-metal-based nanocage capable of specifically acting with cancer cells. The copper / calcium bimetal-based nanocage has the structural characteristics of large specific surface area, moderate particle size and pore size, capability of coordinating and combining a plurality of groups and the like, is high in drug loading capacity, and has pH / glutathione dual responsiveness and Fenton-like catalytic reaction characteristics. According to the invention, the bortezomib and the illicit are loaded in the nanocage through coordination, and the drug loading rates respectively reach 13.9% and 31.7%; the final nanocage has a tumor targeting function and can efficiently trigger cancer cell endoplasmic reticulum stress and nematode damage, and the synergistic amplification effect of the two can significantly enhance the immunotherapy effect.

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

This application provides a pharmaceutical composition and its application for treating liver cancer, relating to the field of biomedical technology. The pharmaceutical composition includes active ingredients, namely the proteasome inhibitor Bortezomib and the Rev-Erb agonist SR9009. By combining the proteasome inhibitor Bortezomib with the Rev-Erb agonist SR9009, synergistic anti-liver cancer activity is observed both in vitro and in vivo, enhancing the mechanism of protein toxicity-induced apoptosis in liver cancer cells. The combined effect of Bortezomib and Rev-Erb agonist SR9009 is significantly superior to either Bortezomib or Rev-Erb agonist alone, overcoming the poor efficacy of Bortezomib monotherapy in liver cancer, and demonstrating significant synergistic effects and clinical application value.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention discloses a medicine for treating multiple myeloma by combining an arginine methyltransferase 5 inhibitor and bortezomib. The invention creatively discloses the synergistic effect of the PRMT5 inhibitor and BTZ combined application in the anti-MM medicine or the medicine composition. The combined medication scheme shows remarkable synergistic anti-tumor activity in vitro and in vivo, the average ZIP synergistic fraction is larger than 10 and is far higher than single drug simple superposition, proliferation of MM cells can be effectively inhibited, cell apoptosis is induced, and the BTZ treatment effect is remarkably improved.

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and / or Ibrutinib

Described herein are liquid compositions comprising: bortezomib; mannitol in an amount up to about 50 mg / mL; and a pharmaceutically acceptable carrier, wherein the liquid composition is for intravenous or subcutaneous use; and wherein the liquid composition comprises not more than (NMT) 1.0% of Impurity-E; Impurity-L; Impurity-J; Impurity-F; Impurity-I; or Impurity-U; and NMT than 3.0% of Total Impurities. Methods of making and using these compositions are also described herein.

This invention relates to the field of pharmaceutical preparations, specifically to a method for preparing a lyophilized bortezomib for injection. The method for preparing a lyophilized bortezomib for injection provided by this invention includes preparing bortezomib mannitol ester and preparing a lyophilized bortezomib for injection. The preparation of bortezomib mannitol ester includes the following steps: adding mannitol to purified water and stirring to dissolve it to form a mannitol solution; adding tert-butanol to the mannitol solution and stirring until homogeneous to form a mixture; adding bortezomib to the resulting mixture and stirring until completely dissolved to form a bortezomib mannitol ester solution; filtering the resulting bortezomib mannitol ester solution, dispensing the filtrate into stainless steel trays, and placing them in a lyophilization chamber; lyophilizing, collecting the lyophilized powder, and obtaining bortezomib mannitol ester. This invention effectively overcomes the problems of foreign matter in lyophilized bortezomib preparations and poor clarity after reconstitution.

The present invention aims to develop a technique for measuring neutrophil counts using small amounts of blood, such as 1 μL or less, as obtained by fingertip puncture. [Solution] A method for measuring the number of neutrophils in a blood sample is provided, which includes measuring superoxide anions in the presence of bortezomib or ixazomib or a salt thereof.

Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a bortezomib lyotropic liquid crystal precursor composition, its preparation method, and its application. The bortezomib lyotropic liquid crystal precursor composition comprises bortezomib and a lyotropic liquid crystal carrier, wherein the ratio of bortezomib to the lyotropic liquid crystal carrier is 0.8-10 mg:1 mL; the lyotropic liquid crystal carrier comprises soybean phosphatidylcholine, α-tocopherol, dioleoylglycerol, and anhydrous ethanol in a mass ratio of 40-48:30-40:10:10-15. Experimental verification shows that the bortezomib lyotropic liquid crystal precursor composition provided by this invention can be converted into a structurally stable liquid crystal phase after subcutaneous injection, achieving effective encapsulation and slow release of bortezomib, thereby significantly prolonging the drug's duration of action in vivo, reducing local reactions, and exhibiting long-acting, safe, and stable characteristics.

The present invention relates to a composition for cancer prevention, comprising a statin-based drug as an active ingredient, and disclosed is that a statin drug known for hyperlipidemia treatment may effectively prevent cancer progression. More specifically, a novel use of rosuvastatin is provided so as to enable providing a composition for multiple myeloma (MM) prevention for inhibiting progression from monoclonal gammopathy of undetermined significance (MGUS) to MM. In addition, the composition may exhibit a greater tumor growth inhibition effect when bortezomib and rosuvastatin are co-administered compared to when each medicine is administered alone.

The present invention provides a composition comprising Bortezomib, a potent anti-cancer agent. More particularly, the present invention relates to a Bortezomib formulation, that is formulated into a stable ready-to-use liquid injectable formulation with refrigeration at 2-8ºC as storage condition. Further, the present invention provides a formulation that is free of a non- aqueous solvent and employs water as the solvent. Further, the present invention relates to a process for preparation of the stable Bortezomib formulation.